JP2024525723A5 - - Google Patents

Info

Publication number
JP2024525723A5
JP2024525723A5 JP2024501737A JP2024501737A JP2024525723A5 JP 2024525723 A5 JP2024525723 A5 JP 2024525723A5 JP 2024501737 A JP2024501737 A JP 2024501737A JP 2024501737 A JP2024501737 A JP 2024501737A JP 2024525723 A5 JP2024525723 A5 JP 2024525723A5
Authority
JP
Japan
Prior art keywords
alkyl
phe
peptide inhibitor
cyano
bicyclic peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024501737A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024525723A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/037202 external-priority patent/WO2023288017A2/en
Publication of JP2024525723A publication Critical patent/JP2024525723A/ja
Publication of JP2024525723A5 publication Critical patent/JP2024525723A5/ja
Pending legal-status Critical Current

Links

JP2024501737A 2021-07-14 2022-07-14 インターロイキン-23受容体の二環式ペプチド阻害剤 Pending JP2024525723A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163221854P 2021-07-14 2021-07-14
US63/221,854 2021-07-14
PCT/US2022/037202 WO2023288017A2 (en) 2021-07-14 2022-07-14 Bicyclic peptide inhibitors of interleukin-23 receptor

Publications (2)

Publication Number Publication Date
JP2024525723A JP2024525723A (ja) 2024-07-12
JP2024525723A5 true JP2024525723A5 (cg-RX-API-DMAC7.html) 2025-07-24

Family

ID=84920518

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024501737A Pending JP2024525723A (ja) 2021-07-14 2022-07-14 インターロイキン-23受容体の二環式ペプチド阻害剤

Country Status (12)

Country Link
US (1) US20240352073A1 (cg-RX-API-DMAC7.html)
EP (1) EP4370532A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024525723A (cg-RX-API-DMAC7.html)
KR (1) KR20240034223A (cg-RX-API-DMAC7.html)
CN (1) CN117980320A (cg-RX-API-DMAC7.html)
AR (1) AR126457A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022310347A1 (cg-RX-API-DMAC7.html)
CA (1) CA3226492A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024000761A (cg-RX-API-DMAC7.html)
TW (1) TW202321275A (cg-RX-API-DMAC7.html)
UY (1) UY39858A (cg-RX-API-DMAC7.html)
WO (1) WO2023288017A2 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4091624A1 (en) 2013-03-15 2022-11-23 Protagonist Therapeutics, Inc. Hepcidin analogues and uses thereof
CA2949215C (en) 2014-05-16 2023-03-14 Protagonist Therapeutics, Inc. .alpha.4.beta.7 integrin thioether peptide antagonists
SG10201810154WA (en) 2014-07-17 2018-12-28 Protagonist Therapeutics Inc Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
WO2018022937A1 (en) 2016-07-27 2018-02-01 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 and their use to treat inflammatory diseases
WO2019157268A1 (en) 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
MX2022008740A (es) 2020-01-15 2022-09-23 Janssen Biotech Inc Peptidos inhibidores del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias.
AU2021383828A1 (en) 2020-11-20 2023-07-06 Janssen Pharmaceutica Nv Compositions of peptide inhibitors of interleukin-23 receptor
KR20240034224A (ko) 2021-07-14 2024-03-13 얀센 바이오테크 인코포레이티드 인터류킨-23 수용체의 지질화된 펩티드 억제제
EP4652181A1 (en) * 2023-01-16 2025-11-26 Janssen Pharmaceutica NV Polycyclic peptide inhibitors of interleukin-23 receptor
EP4471049A1 (en) 2023-06-01 2024-12-04 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
EP4471048A1 (en) 2023-06-01 2024-12-04 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
CN121909205A (zh) 2023-09-08 2026-04-21 赛诺菲 作为选择性il-23受体抑制剂的新型肽
CN121794283A (zh) 2023-09-08 2026-04-03 赛诺菲 作为选择性il-23受体抑制剂的新型肽
WO2025076414A1 (en) * 2023-10-06 2025-04-10 The Children's Medical Center Corporation Compositions and methods for selecting a subject for inflammatory bowel disease treatment
WO2026013260A1 (en) 2024-07-12 2026-01-15 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
WO2026026815A1 (zh) * 2024-07-30 2026-02-05 西藏海思科制药有限公司 白介素-23受体的肽抑制剂及其用途
WO2026041110A1 (zh) * 2024-08-22 2026-02-26 上海瀚辰星泰医药科技有限公司 一种多肽化合物及其应用
WO2026138829A1 (zh) * 2024-12-23 2026-07-02 上海医药集团股份有限公司 多肽抑制剂及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201810154WA (en) * 2014-07-17 2018-12-28 Protagonist Therapeutics Inc Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
WO2016054445A1 (en) * 2014-10-01 2016-04-07 Protagonist Therapeutics, Inc. Novel cyclic monomer and dimer peptides having integrin antagonist activity
HK1257747A1 (zh) * 2015-07-15 2019-10-25 Protagonist Therapeutics Inc. 白细胞介素-23受体的肽抑制剂以及其治疗炎症性疾病的用途
CA3046171A1 (en) * 2016-12-06 2018-06-14 Stichting Voor De Technische Wetenschappen Multicyclic peptides and methods for their preparation
WO2019034866A1 (en) * 2017-08-14 2019-02-21 Bicyclerd Limited BICYCLIC PEPTIDE LIGANDS CONJUGATES AND USES THEREOF
MX2020006290A (es) * 2017-12-15 2020-12-03 Janssen Biotech Inc Dinucleotidos ciclicos como agonistas de sting.
CA3104418A1 (en) * 2018-07-12 2020-01-16 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
AU2020311395A1 (en) * 2019-07-10 2022-02-03 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
TWI860386B (zh) * 2019-07-30 2024-11-01 英商拜西可泰克斯有限公司 異質雙環肽複合物

Similar Documents

Publication Publication Date Title
JP2024525732A5 (cg-RX-API-DMAC7.html)
JP2024525780A5 (cg-RX-API-DMAC7.html)
JP7604666B2 (ja) 代謝及び肝臓障害の処置のための組成物及び方法
USRE50554E1 (en) Amino acid compounds and methods of use
JP2023511551A5 (cg-RX-API-DMAC7.html)
TW202332683A (zh) 介白素-23受體之肽抑制劑
JP2024525723A (ja) インターロイキン-23受容体の二環式ペプチド阻害剤
TW202330013A (zh) 介白素-23受體之脂化肽抑制劑
JP2023145581A (ja) インターロイキン-23受容体のペプチド阻害剤の組成物
SG11202110624YA (en) Itaconic acid derivatives and uses thereof in treating an inflammatory disease or a disease associated with an undesirable immune response
CA3181676A1 (en) Imidazopyridazines as modulators of il-17
Liu et al. Synthetic approaches to the 2009 new drugs
CN103502236B (zh) 非晶态(5-氟-2-甲基-3-喹啉-2-基甲基-吲哚-1-基)-乙酸
CN102264694B (zh) 用于制备伏立诺他的方法
US20240010606A1 (en) Fumarate derivatives and their medical use
JP2021530477A5 (cg-RX-API-DMAC7.html)
TWI911262B (zh) 化合物、組合物及方法
CN117550990B (zh) 用于合成(s)-3-氨基-4-(二氟亚甲基)环戊-1-烯-1-甲酸的工艺
US20230399289A1 (en) Itaconic acid derivatives
US11306098B2 (en) Substituted pyrrolo[1,2-a]pyrazines and pyrrolo[1,2-a][1,4]diazepines as TREX1 inhibitors
WO2015130964A1 (en) Therapeutic compounds
US20220001015A1 (en) Lymphatic system-directing lipid prodrugs
CN114746394B (zh) 一种芳基丙酸衍生物、药物组合物及其制备方法和应用
AU2018374863B2 (en) Compositions and methods relating to salts of specialized pro-resolving mediators
US7109224B2 (en) Acyl guanidine compounds and use thereof